May 10, 2024Recently, Beilu Pharmaceutical received a Drug Registration Certificate from the National Medical Products Administration for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets with a s...view
June 20, 2023The company's product, Jiuwei Zhenxin Granules, has been included in the "Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Bipolar Depression...view
April 21, 2021Recently, Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA).view
April 25, 2025Recently, Beilu Pharmaceutical (300016) released the "2025 First Quarter Report". Building on the stable growth in annual performance in 2024, Beilu Pharmaceutical has had a great start in 2...view
June 6, 2023Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...view
November 1, 2024Recently, Beijing Beilu Pharmaceutical Co., Ltd.'s contrast agent production linepassed the GMP (Good Manufacturing Practice) certification by Brazil's National Health Surveillance Agency (ANV...view